Share
   
Title
Code
Session Type
Venue
Date Time
Chair:
Organizer:

This session highlights game-changing innovations for paediatric HIV diagnosis, novel treatment formulations and monitoring; discusses evidence supporting scale-up, and describes opportunities and barriers to access to these innovations that complement the role of PMTCT programs. In diagnosis, we highlight the role of point-of-care (POC) early infant diagnosis (EID) to enhance case finding by improving access to EID in high-yield entry points, increase the proportion of infants receiving timely diagnosis and linkage to treatment. In treatment, we share experiences of new child-friendly formulations that are being rolled out and highlight optimal formulations in late stage development that will improve clinical outcomes. The session also discusses the potential role of targeted POC viral load monitoring, for pregnant and breastfeeding women, to better identify infants at high risk of infection and target prevention efforts. Finally, the session will showcase experiences from Cameroon, Kenya and Zimbabwe, where these innovative solutions are being implemented.

12:30
MOSA3001
Welcome remarks and Introduction
Smiljka de Lussigny, Unitaid, Switzerland
Nqobile Ndlovu, ASLM, Ethiopia
12:45
MOSA3002
Diagnosis ā€“ Innovations to meet the first 90
Rebecca Bailey, Elizabeth Glaser Pediatric AIDS Foundation, Switzerland
Trevor Peter, CHAI, United States
13:00
MOSA3003
Treatment - New child-friendly formulations to meet the second 90
Dr Victor Musiime, Makerere University, Uganda
Slides
13:15
MOSA3004
Panel Discussion - Optimizing POC and treatment to reach all three ā€˜90sā€™ including viral load suppression
Raiva Simbi, Ministry of Health and Child Care, Zimbabwe
Prof. Dalton Wamalwa, Kenyatta Hospital/ University of Nairobi, Kenya
Maurine Murenga, Lean on Me Foundation., Kenya
Patrice Tchendjou, Elizabeth Glaser Pediatric AIDS Foundation, Cameroon
Dr. Surbhi Modi, CDC, United States
13:45
MOSA3005
Question & Answer - Open questions from the floor to speakers and panelists
14:20
MOSA3006
Closing statements
Shaffiq Essajee, WHO, Switzerland
Siberry George, PEPFAR, United States